Abstract
<p> </p> <p><strong>Objective</strong><br> We investigated endotrophin, a profibrotic signaling molecule reflecting collagen VI formation, in serum and urine as risk marker for complications to type 2 diabetes.<br> <strong>Research Design and Methods</strong><br> Endotrophin was measured in 774 persons with type 2 diabetes. Outcomes included a composite kidney endpoint, first major adverse cardiovascular event (MACE), mortality, progression of albuminuria, incident heart failure and sight-threatening eye disease. Adjusted cox proportional hazards models were applied.<br> <strong>Results</strong></p> <p>Doubling of serum endotrophin was associated with the kidney endpoint (n=49, HR:1.80 (95% CI: 1.13-2.87), first MACE (n=66, HR:1.54 (1.04-2.28)), mortality (n=156, HR:1.69 (1.31-2.19)) and incident heart failure (n=42, HR:1.63 (1.02-2.60)). A doubling of urine endotrophin was associated with progression of albuminuria (n=85, HR:1.20 (1.04-1.39)) and incident heart failure (n=40, HR:1.79 (1.09-2.95)).</p> <p><strong>Conclusions </strong><br> Serum endotrophin was a risk marker for mortality, kidney and cardiovascular complications in type 2 diabetes. Urine endotrophin was a marker for albuminuria progression and heart failure.</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
